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ABSTRACT
The definition of the role of positron emission tomography
(PET) in peripheral T-cell lymphomas (PTCLs) is still under
investigation. The purpose of the present observational
retrospective study was to assess the early prognostic value
of PET after the first three cycles of therapy (PET13),
evaluating visual data in de novo PTCL patients treated in first
line with standard chemotherapy and followed by both PET
and computed tomography scan. Of 27 PET13-negative
patients, 19 also had a negative PET at the end of treatment
(PET16), whereas 8 of 27 had a positive final one; 6 of 7 PET1
3-positive patients had a positive PET16, whereas only 1
patient had a negative PET16. Estimated overall survival
plotted according to PET13 results showed 78.6% for
negative patients and 21.4% for positive patients at 88.7
months with a significant difference. Patients with negative
PET13 had superior progression-free survival of 72.6%
compared with 16.7% of PET13-positive patients. At the
time of this analysis, 17 of 19 (89.5%) patients with negative
PET13 are in continuous complete response (CCR) and only 1
of 7 (14.2%) patients with positive PET13 is still in CCR. In
conclusion, our results indicate that positive PET13 is predictive
of a worse outcome in PTCL, and this significant statistical
difference between the two curves could be clinically in-
formative. Larger and prospective studies and harmoniza-
tion of PET reading criteria are needed.The Oncologist 2014;
19:746–750
Implications forPractice: Interimcomputed tomography is themost frequent tool for interimassessment in T-cell lymphomas, but
positronemission tomography (PET) couldbeavalid imaging support.Our study indicates that interimPETresults are independent
predictors of progression-free and overall survival. In addition, our data seem to show the important implication of interim PET in
earlier identification of the potential candidates for an intensive therapeutic strategy with the aim of improving their clinical
outcome.
INTRODUCTION
The different lymphoma histologies present different 18F-
fluorodeoxyglucose (FDG) avidity: for example, several sub-
types—Hodgkin’s lymphoma, diffuse large B-cell lymphoma,
and mantle cell lymphoma—are routinely FDG-avid [1–3].
Several studies have confirmed interim positron emission
tomography (PET) as an early prognostic factor [4–7].
Observations for non-Hodgkin’s lymphomas are mainly based
on B-cell lymphomas, whereas only a few studies with
a relatively small number of patients have investigated the
role of PET in T-cell and natural killer (NK)-cell lymphomas.
PET data in peripheral T-cell lymphoma (PTCL) are limited
and suggest that FDG avidity is less predictable in PTCL than in
other lymphomas [8–12].The role of PET in T-cell lymphomas is
still under investigation. Recently, in fact, Feeneyet al. reported
variations in PET positivity and maximum standardized uptake
value across the different T-cell lymphoma subtypes [13]. PET
positivity ranged from 50% in cutaneous anaplastic large-cell
lymphoma (ALCL) to 78% in angioimmunoblastic T-cell
lymphoma (AITL) to 100% in adult T-cell leukemia/lymphoma.
Twenty-nine percent of patients had sites of disease that
were not picked up on diagnostic total body computed
tomography (CT) scan. The sites that were not detected by CT
scan included cutaneous, subcutaneous, andmuscularmasses
of the scalp and upper and lower extremities, and lymphade-
nopathies in the epitrochlear and popliteal regions, indicating
a probable role of PET imaging from vertex to feet for patients
with T-cell lymphoma [14, 15].The use of PETscan is therefore
very useful in pointing out disease involvement in anatomical
sites not detected by CT scan. Recently, Casulo et al. reported
retrospective data showing PET as an early indicator of
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chemosensitivity in both previously untreated and relapsed
PTCL patients [16].
The purpose of the present study was to evaluate the
prognostic utility of an interim PETscan following three cycles
of cyclophosphamide, doxorubicin, vincristine, and predni-




An observational retrospective study was conducted. After
obtaining approval from our institutional review board,
a computer-based search into our electronic registry was
performed to identify patients receiving initial therapy for
PTCL. Cases were consecutively considered to avoid selection
bias. Written informed consent was obtained from the
identified alive patients to collect retrospectively their data.
Furthermore, the Italian law, through the Ethical Committee,
allowscollectingdataofdeadpeopleorofpatientswhoare lost
at follow-up to prevent bias in researches. The main inclusion
criteria were diagnosis of PTCL according to the World Health
Organization (WHO) classification, standard chemotherapy in
first line, and availability of PET and CT scans at baseline, ad
interim, and at final restaging (end of treatment).
From September 2003 to July 2010, 34 advanced-stage
patients were diagnosed and then treated at our institute. All
diagnostic biopsies were reviewed by an expert pathologist
(SP) to ensure that diagnoses of PTCL were in accordancewith
the WHO classification.
Complete tumor stagingwas performed at baseline by PET
scan (eyes tomidthigh). CTscan of the neck, thorax, abdomen,
and pelvis, both with and without administration of contrast
agent (i.v.), and bone marrow biopsy were also performed.
Disease stage was established according to the Ann Arbor
staging system [17]. Bulky diseasewasdefined as the presence
of a mediastinal mass more than one third of transthoracic
diameteror anextranodalmasswith themajor diameterequal
to or greater than 7 cm, as documented on the CT scan. At
Table 1. Patient characteristics
Characteristic Statistic
n 34








Peripheral T-cell lymphoma not
otherwise specified
11 (32.4)
Angioimmunoblastic T-cell lymphoma 6 (17.6)
ALCL ALK1 9 (26.5)
ALCL ALK2 6 (17.6)







Bulky disease, n (%)
Yes 4 (11.8)
No 30 (88.2)
Bone marrow involvement, n (%)
Yes 8 (23.5)
No 26 (76.5)
Extranodal involvement, n (%)
Yes 15 (44.1)
No 19 (55.9)
Abbreviations: ALCL ALK, anaplastic large-cell lymphoma anaplastic
lymphoma kinase; IPI, international prognostic index; PIT, prognostic
index for T-cell lymphoma.
Figure 1. Progression-free survival of peripheral T-cell lymphoma
patients with positive positron emission tomography after three
cycles of treatment (dashed line) versus those with negative
positron emission tomography (solid line) (p5 .02).
Figure 2. Overall survival of peripheral T-cell lymphoma patients
with positive positron emission tomography after three cycles of
treatment (dashed line) versus those with negative positron
emission tomography (solid line) (p5 .02).
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each visit, patients’ performance status and vital parameters
were recorded, and physical examination, along with com-
plete blood sampling, was performed.
Treatment
As per institutional guidelines, induction chemotherapy for
PTCL consisted of 6 cycles of CHOP chemotherapy regimen
every 21 days. InterimPET (PET13) evaluationwas performed
after completion of the third cycle of therapy, immediately
before the fourth cycle. At the end of treatment, all patients
were completely restaged: both PET (PET16) and CT scans
were performed at least 1 month (61 week) after the end of
therapy.
Efficacy and Safety Assessments
Relapse was determined after a complete response (CR) when
new disease was identified; in patients with partial response
(PR) or stable disease (SD), relapse or progressionwas defined
as an increaseof at least50% in theproducts of thediameterof
any previously identified individual abnormality or with the
appearance of any new lesion. Disease recurrences were
always confirmed by biopsy. PET data were reviewed by the
same expert reader assessing visual data according to the
criteria of the International Harmonization Project [18]. Long-
term outcome and further prospective therapies (including
stem cell transplantation) were also considered. Safety and
tolerabilitywere assessed by recording the incidence, severity,
and type of any adverse events, which were graded according
to the WHO criteria for toxicity (National Cancer Institute
Common Terminology Criteria of Adverse Events v4.0).
Responses were classified according to the International
Workshop for ResponseCriteria for non-Hodgkin’s lymphomas
[19].
Statistical Analysis
Demographics and patients’ characteristics were summarized
by descriptive statistics. Progression-free survival (PFS) was
measured from the date of start of treatment to the date of
either lymphomaprogression or death as a result of any cause.
Overall survival (OS) was measured from the date of diagnosis
to the date of death from any cause. Survival functions were
estimated by using the Kaplan-Meier method and were com-
paredusing log-rank tests. Statistical analyseswereperformed
with Stata 11 (StataCorp, College Station, TX, http://www.
stata.com) and p values were set at .05.
RESULTS
Patient Characteristics
The demographic details of the patients are summarized in
Table 1. Of the 34 patients, 9 (26.5%) presented with stage III
and the remaining 25 (73.5%) had stage IV. Fifteenweremales
and19were females; themedian age atdiagnosiswas 46years
(range, 21–81 years). B-symptoms were present in 14 (41%)
patients, and bulky disease was documented in 4 (12%)
patients; 8 (23.5%) patients showed bone marrow involve-
ment at baseline and 15 (44%) patients had one extranodal
site. According to the histology, there were 11 PTCL-not
otherwise specified, 15 ALCL (9 anaplastic lymphoma kinase
[ALK] positive and 6 ALK negative), 6 AITL, and 2 NK/T-cell
lymphoma.
Sixteen patients underwent autologous stem cell trans-
plantation (ASCT): in particular, 8 patients as consolidation of
response (partial or complete response after the induction
phase with CHOP regimen) and 8 as second-line treatment.
Response
Twenty-seven patients (79.5%) had a negative and 7 (20.5%)
had a positive PET13. Twenty patients (59%) had a negative
and14 (41%)had apositive PET16.Only 1of 7PET13-positive
patient converted to negative at PET16, whereas only 8 of 27
(29.6%) PET13-negative cases had a positive PET16. No
common characteristics in patients who never achieved a PET
CR were observed. After three cycles, the 7 PET-positive
patients obtained the following responses: 6 partial responses
and1progression ofdisease. At the endof therapy, 20patients
(59%) achieved CR, 3 (9%) PR, and 11 (32%) were non-
responders because of progression of disease (PD) or disease
recurrence. The concordance between clinical CR and PET16
negativity was 100%. PET did not downgrade CT responses.
Figure 3. Overall survival of peripheral T-cell lymphoma patients
who underwent autologous stem cell transplantation (dashed
line) and those who did not (solid line) (p5 .17).
Figure 4. Overall survival of peripheral T-cell lymphoma patients
who performed autologous stem cell transplantation as second-
line treatment (solid line) and patients who performed it for
response consolidation (dashed line) (p5 .08).
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Atamedian follow-upof36months, patientswithnegative
PET13hadsuperiorPFSof73%ascomparedwith17%ofPET1
3-positive patients (p5 .02) (Fig. 1). Figure 2 showsOS plotted
according toPET13 results: 79% fornegativepatients and21%
for positive patients at 89 months (p5 .02).
In Figure 3, the OS curves are plotted for two different
groups: 60% for those patients who did not undergo ASCT and
59% for patientswho underwent ASCT, at 115months (p value
is not statistically significant). Figure 4 summarizes the OS
curves for the 16 patients who underwent ASCT: 47% for
patients who performed ASCT in second-line treatment and
71% in patients for whose ASCTwas consolidation treatment.
The difference between the two curves is not statistically
significant. There was a PFS difference for patients who had
a positive versus negative PET after therapy going into
transplant (100% for negative patients vs. 14.3% for positive
patients, p5 .0047).
With amedian follow-up of 4 years, OS for thewhole study
population was 65% (13 deaths; Fig. 5A) and PFS was 61% at
115 months (Fig. 5B). At the time of present analysis, 17 of 19
(89.5%) patients with negative PET13 are in continuous CR
(CCR) and only 1 of 7 (14%) patientswith positive PET13 is still
in CCR. The outcomes for patients who were PET negative but
became positive were as follows: 6 patients underwent ASCT
(at the latest follow-up 3 were dead, 1 alive in PD, and 2 in CR
after further therapies); the other 2 patients died because of
PD after subsequent therapies.
DISCUSSION
PEThas becomean important component of themanagement
of patients with B-cell non-Hodgkin’s and Hodgkin’s lym-
phoma. However, the role of PET in PTCL is still under
investigation.There is no recommendation for the routine use
of PET in PTCL as studies focusing on the prognostic value of
interimor post-therapy PET are indeed rare and the results are
contradictory [14, 20, 21]. BecausemostPTCLs arenotcurable,
PET should be used for restaging only if CR is a major study
endpoint.
Recently, Cahu et al. analyzed the role of interim PET in 54
patientswithNK/T-cell lymphomasandconcluded that there is
no significant difference in terms of OS and PFS between
patients with negative versus positive interim PET [22]. On the
contrary, Casulo et al. reported on 94 PTCL patients (the
interim restaging cohort included only 50 patients); patients
with negative interim PET had superior PFS compared with
patients with positive interim PET [16]; regarding OS, there
were no differences.
In the present study, the prognostic value of interim PET
was assessed in a series of 34 patients with PTCL. Our data
indicate that persistent FDG uptake after three cycles of
therapy can be predictive of PFS and OS: only 14% of patients
with a positive interim PETscan achieved CCR,whereas almost
all patients (89.5%)with a negative scan are in CCR.The strong
prognostic impact of a negative interim PET scan is also
confirmed by a 3-year PFS rate of 73% and a 3-year OS rate of
79%. As no common characteristics in patients who never
achievedaPETCRwere found, itcould indicatethat interimPET
has an independent prognostic value.Table 2 summarizes four
recent reports indicating the discordant situation regarding
the role of interim PET in PTCL, but three of the studies are
similar for the significant association between interim PET
findings and PFS data.
Like previous retrospective studies, our study has some
limitations, including the relatively small size of our cohort and
the inclusion of ASCT in the initial therapy program of some
patients as probable confounding bias [16, 21, 22]. Notewor-
thy, in comparison with the others in whom there was an
important variation in front-line chemotherapy regimen, we
Figure 5. Overall (A) and progression-free (B) survival of whole study population.
Table 2. Recent reports on interim PET role in peripheral T-cell lymphoma
Report Patients (n)
Overall survival: interim PET2 vs.
interim PET1
Progression-free survival: interim PET2 vs.
interim PET1
Cahu et al. [22] 54 76% vs. 47% (p5 .16 at 4 years) 69% vs. 49% (p5 .10 at 4 years)
Casulo et al. [16] 50 65% vs. 48% (p5 .17 at 3 years) 63% vs. 25% (p5 .03 at 3 years)
Li et al. [21] 88 80% vs. 47% (p5 .02 at 2 years) 72% vs. 21% (p, .001 at 2 years)
This study 34 79% vs. 21% (p5 .02 at 3 years) 73% vs. 17% (p5 .02 at 3 years)
Abbreviation: PET, positron emission tomography.
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reported on a more homogenous cohort as induction therapy
was the same for all the study population. In addition, all our
patients underwent interim PET after 3 cycles; in the other
reports, there were evident variations in the interval between
end of treatment (range, 1–10 cycles) and interim PET.
Furthermore, previous studies reported a limited number of
patients with baseline PET [16, 21, 22].
CONCLUSION
Despite these limitations, our study indicates that interim PET
results are independent predictors of PFS and OS in PTCL
patients. In addition, our data seem to show the important
implication of interim PET in the earlier identification of
potential candidates for an intensive therapeutic strategywith
the aim of improving their clinical outcome. Larger and
perspective studies with uniform front-line chemotherapy
regimen and interim PET timing are needed to better evaluate
the prognostic role of interim PET in PTCL patients.
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